Jawad A. Alrawabdeh

Amman, AM, Jordan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Journal: Blood cancer journal

Published: August 07, 2026

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Journal: Blood cancer journal

Published: November 30, 2025

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Journal: Blood cancer journal

Published: September 08, 2025

Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience.

Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience.

Journal: Bone marrow transplantation

Published: December 16, 2024

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.

Journal: Blood advances

Published: December 16, 2024

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.

Journal: Clinical hematology international

Published: July 29, 2024

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab.

Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab.

Journal: EJHaem

Published: April 24, 2024

Glutathione and Xanthine Metabolic Changes in Tamoxifen Resistant Breast Cancer Cell Lines are Mediated by Down-Regulation of GSS and XDH and Correlated to Poor Prognosis.

Glutathione and Xanthine Metabolic Changes in Tamoxifen Resistant Breast Cancer Cell Lines are Mediated by Down-Regulation of GSS and XDH and Correlated to Poor Prognosis.

Journal: Journal of Cancer

Published: March 26, 2024

Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.

Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.

Journal: JCO global oncology

Published: February 29, 2024

B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.

B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.

Journal: EJHaem

Published: February 01, 2024

The Impact of War Trauma and Housing Environment on Mental Wellbeing of Syrian Refugees in Jordan: A Comparison between In-Camp and Urban Populations.

The Impact of War Trauma and Housing Environment on Mental Wellbeing of Syrian Refugees in Jordan: A Comparison between In-Camp and Urban Populations.

Journal: Issues in mental health nursing

Published: February 01, 2024

Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review.

Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review.

Journal: JNCI cancer spectrum

Published: August 13, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026